Antimalarial drug resistance and combination chemotherapy.
about
Challenges of drug-resistant malariaChanges in the treatment responses to artesunate-mefloquine on the northwestern border of Thailand during 13 years of continuous deploymentAntimalarial drug resistanceIdentification of an antimalarial synthetic trioxolane drug development candidateArtemether-lumefantrine (six-dose regimen) for treating uncomplicated falciparum malariaArtemether-lumefantrine (four-dose regimen) for treating uncomplicated falciparum malariaEvolution of resistance to sulfadoxine-pyrimethamine in Plasmodium falciparumArtemisinin combination therapy for vivax malariaAssociation of house spraying with suppressed levels of drug resistance in ZimbabweEpidemiological models for the spread of anti-malarial resistanceA systematic review of the efficacy of a single dose artemisinin-naphthoquine in treating uncomplicated malariaCurcumin-arteether combination therapy of Plasmodium berghei-infected mice prevents recrudescence through immunomodulationMathematical Modelling to Guide Drug Development for Malaria EliminationHigh efficacy of artemether-lumefantrine and declining efficacy of artesunate + sulfadoxine-pyrimethamine against Plasmodium falciparum in Sudan (2010-2015): evidence from in vivo and molecular marker studiesDuration of protection against clinical malaria provided by three regimens of intermittent preventive treatment in Tanzanian infantsPlasmodium falciparum: differential selection of drug resistance alleles in contiguous urban and peri-urban areas of Brazzaville, Republic of CongoEfficacy and safety of artemether in the treatment of chronic fascioliasis in Egypt: exploratory phase-2 trialsFive years of antimalarial resistance marker surveillance in Gaza Province, Mozambique, following artemisinin-based combination therapy roll outAssessment of Markers of Antimalarial Drug Resistance in Plasmodium falciparum Isolates from Pregnant Women in Lagos, NigeriaCharacterization of Novel Antimalarial Compound ACT-451840: Preclinical Assessment of Activity and Dose-Efficacy ModelingMefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy numberGene encoding a deubiquitinating enzyme is mutated in artesunate- and chloroquine-resistant rodent malaria parasitesThe effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of individual patient dataTwo fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison.cDNA sequences reveal considerable gene prediction inaccuracy in the Plasmodium falciparum genome.Plasmodium falciparum: development of a transgenic line for screening antimalarials using firefly luciferase as the reporter.A nationwide survey of the quality of antimalarials in retail outlets in TanzaniaIdentification and optimization of an aminoalcohol-carbazole series with antimalarial properties.Experimental evolution of resistance to artemisinin combination therapy results in amplification of the mdr1 gene in a rodent malaria parasite.Five years of large-scale dhfr and dhps mutation surveillance following the phased implementation of artesunate plus sulfadoxine-pyrimethamine in Maputo Province, Southern Mozambique.Combinations of artemisinin and quinine for uncomplicated falciparum malaria: efficacy and pharmacodynamics.The antimalarial ferroquine: from bench to clinic.Prospective strategies to delay the evolution of anti-malarial drug resistance: weighing the uncertainty.A study protocol for a randomised open-label clinical trial of artesunate-mefloquine versus chloroquine in patients with non-severe Plasmodium knowlesi malaria in Sabah, Malaysia (ACT KNOW trial).Artemisinin drugs: novel antimalarial agents.In vitro potentiation of antibiotic activities by a catecholate iron chelator against chloroquine-resistant Plasmodium falciparum.Artemisinin pharmacokinetics and efficacy in uncomplicated-malaria patients treated with two different dosage regimensIn vitro sensitivity of Plasmodium falciparum clinical isolates from the China-Myanmar border area to quinine and association with polymorphism in the Na+/H+ exchanger.Modelling parasite drug resistance: lessons for management and control strategies.The evolution of drug-resistant malaria: the role of drug elimination half-life
P2860
Q21032482-4533C5AA-6483-4CA8-A394-6C73D2841497Q21090072-686C9645-0919-478F-9CC4-0EAD8BBBCB7DQ22061790-F0244E53-80C0-4068-B4D1-F0A3483B03D4Q22061876-0E714FE9-15A1-40EE-96A0-CCBBE811573EQ24245437-6955B7CF-99CE-486A-B542-1F0F22E604BDQ24246332-10111E06-1E54-4960-A161-B04C10CE2074Q24563685-9A5BD24E-1621-4121-8B48-BF36992B2E1EQ24622539-E36A2286-C100-45FD-B294-A730E9C96026Q24803104-7D662742-EA66-4FEB-B7A9-B2326497E77AQ24805506-51226099-632B-49C4-8233-625AFACBAB48Q26786586-CDF15E38-2C62-4084-BD6E-314002812FAEQ27310654-C29CAE90-6C15-4258-A197-4EF7B30CED2FQ28067367-374D06C9-5D55-491A-AC62-5F7416B0713FQ28125935-1AB18CE4-9946-4FBA-BC05-19FAFEDBE661Q28473083-F3DCED49-F4B8-478F-AEB2-9DDFEC28B2E7Q28476554-A0267F84-370C-4FB7-BCE6-39C420A526D3Q28476800-8CD6467B-B825-450D-ABCA-85E495325274Q28477515-8BC0321D-0EF3-41DC-BCF9-A00671CB27E4Q28552844-A4F72B01-2BD8-4F20-88BA-D4692D95B300Q28554466-00FA428D-3950-4F04-B0F4-639C2E5611DDQ29615128-CA85C1E3-D58C-4132-B1A2-50593AA07F3BQ30362459-60272919-8E06-4A4D-B4EF-61826F0FE040Q30936416-D4743824-ABFD-4DE5-AB63-70AD873A614CQ33276757-653EC258-65BE-48E4-B2AB-F9245628593BQ33292248-417A1804-9D45-4A04-91E1-A63E83E9B3BDQ33346695-9E270140-403C-40D3-BDA5-78C41146E693Q33377031-C802A7D9-1192-447A-8696-98B529F1C4E7Q33636074-CBE69C6E-D539-45BD-9473-0DDCC04445B6Q33640021-DB27C3DF-CF23-4FAF-AE71-A673B8A37209Q33817503-6BA57E44-C102-42FC-9079-7A3BB40CF263Q33979461-0C87C184-6C23-4504-A0E6-3244B4FE1339Q34028399-6F307595-C62C-4AE7-BF23-169D64BA600EQ34047599-A49C43B5-9C5C-45BC-9D2E-85EC7EE691E5Q34071772-88B3CB10-5710-4DDF-AF36-DD441063AA41Q34075018-46D5781C-A916-444D-87B7-ABFCED41AFA7Q34104791-9710237E-E9B0-42D6-97B0-355350D3B347Q34105652-CCA5B99C-8B9C-4879-9A87-8004D71068ABQ34151002-2E55C8F8-2EF9-4AED-B2B4-FA1D45F08FC4Q34434816-A2602B4B-AD2A-4B3C-8D0B-062EAD4216D5Q34655810-9EF1DD26-E752-4405-AAE3-4ECF3874D62F
P2860
Antimalarial drug resistance and combination chemotherapy.
description
1999 nî lūn-bûn
@nan
1999 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Antimalarial drug resistance and combination chemotherapy.
@ast
Antimalarial drug resistance and combination chemotherapy.
@en
type
label
Antimalarial drug resistance and combination chemotherapy.
@ast
Antimalarial drug resistance and combination chemotherapy.
@en
prefLabel
Antimalarial drug resistance and combination chemotherapy.
@ast
Antimalarial drug resistance and combination chemotherapy.
@en
P2860
P356
P1476
Antimalarial drug resistance and combination chemotherapy.
@en
P2093
P2860
P304
P356
10.1098/RSTB.1999.0426
P407
P577
1999-04-01T00:00:00Z